



(11) Publication number: **0 294 993 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(43) Date of publication of patent specification:  
03.07.91 Bulletin 91/27

(51) Int. Cl.<sup>5</sup>: **A61K 9/44, A61K 9/22,  
A61K 9/24, A61L 9/12**

(21) Application number: **86304974.4**

(22) Date of filing: **01.06.88**

(54) **A generic zero order controlled drug delivery system.**

(30) Priority: **11.06.87 US 61925**

(43) Date of publication of application:  
14.12.88 Bulletin 88/50

(46) Publication of the grant of the patent:  
03.07.91 Bulletin 91/27

(84) Designated Contracting States:  
**AT BE CH DE ES FR GB GR IT LI LU NL SE**

(56) References cited:  
**EP-A- 0 153 070  
EP-A- 0 200 224  
EP-A- 0 205 342  
AT-B- 341 100  
AT-B- 374 366**

(56) References cited:  
**DE-A- 3 613 433  
GB-A- 1 372 040  
GB-A- 2 110 524  
US-A- 2 539 036  
US-A- 3 146 169  
US-A- 3 851 648**

(73) Proprietor: **PFIZER INC. -  
235 East 42nd Street  
New York, N.Y. 10017 (US)**

(72) Inventor: **Ranade, Gautam Ramchandra  
18 Wayne Drive  
East Lyme Connecticut 06333 (US)**

(74) Representative: **Bradbrook, Geoffrey William  
et al  
PFIZER LIMITED Ramsgate Road  
Sandwich Kent, CT13 9NJ (GB)**

**EP 0 294 993 B1**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Jouv , 18, rue Saint-Denis, 75001 PARIS

**BEST AVAILABLE COPY**